SE stock is rated Hold due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART.

Latozinemab failure, with Nivisnebart Phase 2 data as the next key catalyst. Click here to read more about ALEC stock.

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women from the virus in a large phase 3 trial, the biotech announced in a ...

The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay at slowing the rate of retina lesion growth, the primary ...